Agenus tunjuk Marco Tullio Marcucci sebagai direktur baru dewan komisarisPUBT·Aug 11 at 03:35 PMAGEN+4.57%
Agenus Inc. Reports No Material Changes to Previously Disclosed Risk Factors in Latest ReviewTip Ranks·Aug 10 at 01:01 AMAGEN+4.57%
Agenus advances Phase 3 ROBBIN trial of botensilimab-balstilimab in neoadjuvant MSS colon cancerPUBT·Aug 6 at 06:53 AMAGEN+4.57%
Agenus posts corporate presentation spotlighting botensilimab-balstilimab neoadjuvant strategy in MSS colon cancerPUBT·Jul 30 at 09:27 AMAGEN+4.57%
Mid-Cap Tech and Healthcare Face Critical Tests: From Delisting Risks to Mega FinancingsGlobal Report·Jul 26 at 04:15 AMCYCU-2.14%BJDX-0.94%
M&A, Poison Pills, and Capital Restructuring Drive US Mid-Cap RealignmentsGlobal Report·Jul 25 at 04:13 AMDKL+3.27%CISS-3.06%
Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focusrttnews·Jul 23 at 10:24 PMNVCR-2.47%MEDP-0.59%
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | AGEN Stock NewsStockTitan·Jul 17 at 01:28 AMAGEN+4.57%
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focusrttnews·Jul 13 at 09:35 PMAGEN+4.57%SI+7.80%
